FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

Cancer Science

Volumn 107, Issue 11, 2016, Pages 1667-1676

  Hibi, Masaaki ^a   Kaneda, Hiroyasu ^a,b   Tanizaki, Junko ^a   Sakai, Kazuko ^a   Togashi, Yosuke ^a   Terashima, Masato ^a,c   De Velasco, Marco Antonio ^a   Fujita, Yoshihiko ^a   Banno, Eri ^a   Nakamura, Yu ^a   Takeda, Masayuki ^a   Ito, Akihiko ^a   Mitsudomi, Tetsuya ^a   Nakagawa, Kazuhiko ^a   Okamoto, Isamu ^d   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY   (Japan)

^b Kishiwada City Hospital   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Copy number gain; FGFR1; lung squamous cell cancer; next generation sequencing; nintedanib

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; NINTEDANIB; PROTEIN KINASE B; FGFR1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; INDOLE DERIVATIVE; MUTANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG TARGETING; FEMALE; FGFR GENE; FGFR1 GENE; FGFR2 GENE; FGFR3 GENE; GENE FUSION; GENE MUTATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG CANCER CELL LINE; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; SQUAMOUS CELL LUNG CARCINOMA; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR RECURRENCE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MICE; MOLECULAR TARGETED THERAPY; MUTANT PROTEINS; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84997820988     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13071     Document Type: Article

References (44)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
2. Travis WD, Brambilla E, Nicholson AG et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243–60.
3. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 2016; 10: 113–29.
4. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543–51.
5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24.
6. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–34.
7. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061–8.
8. Wells SA Jr, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134–41.
9. Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett 2015; 358: 59–66.
10. Reck M, Kaiser R, Eschbach C et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011; 22: 1374–81.
11. Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143–55.
12. Eisen T, Loembe AB, Shparyk Y et al. A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. Br J Cancer 2015; 113: 1140–7.
13. Ledermann JA, Hackshaw A, Kaye S et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29: 3798–804.
14. Droz JP, Medioni J, Chevreau C et al. Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. Anticancer Drugs 2014; 25: 1081–8.
15. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211–25.
16. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 2016; 22: 259–67.
17. Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085–94.
18. Matsumoto K, Arao T, Hamaguchi T et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012; 106: 727–32.
19. Gust KM, McConkey DJ, Awrey S et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther 2013; 12: 1245–54.
20. Taylor JG, Cheuk AT, Tsang PS et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009; 119: 3395–407.
21. Kawamura-Akiyama Y, Kusaba H, Kanzawa F, Tamura T, Saijo N, Nishio K. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. Lung Cancer 2002; 38: 43–50.
22. Nishio K, Arioka H, Ishida T et al. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int J Cancer 1995; 63: 688–93.
23. Narahara M, Higasa K, Nakamura S et al. Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants. PLoS One 2014; 9: e100924.
24. Lonigro RJ, Grasso CS, Robinson DR et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 2011; 13: 1019–25.
25. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401–4.
26. Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
27. Weiss J, Sos ML, Seidel D et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
28. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883–93.
29. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519–25.
30. Tiseo M, Gelsomino F, Alfieri R et al. FGFR as potential target in the treatment of squamous non small cell lung cancer. Cancer Treat Rev 2015; 41: 527–39.
31. Heist RS, Mino-Kenudson M, Sequist LV et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012; 7: 1775–80.
32. Goke F, Franzen A, Menon R et al. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 2012; 142: 1020–6.
33. Kim HS, Mitsudomi T, Soo RA, Cho BC. Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer 2013; 80: 249–55.
34. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069–75.
35. Abaan OD, Polley EC, Davis SR et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 2013; 73: 4372–82.
36. Wang R, Wang L, Li Y et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res 2014; 20: 4107–14.
37. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013; 22: 795–803.
38. Wu YM, Su F, Kalyana-Sundaram S et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013; 3: 636–47.
39. Xie L, Su X, Zhang L et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 2013; 19: 2572–83.
40. Li SQ, Cheuk AT, Shern JF et al. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One 2013; 8: e76551.
41. Liao RG, Jung J, Tchaicha J et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013; 73: 5195–205.
42. Capelletti M, Dodge ME, Ercan D et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 2014; 20: 6551–8.
43. Di Stefano AL, Fucci A, Frattini V et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res 2015; 21: 3307–17.
44. Kim HS, Lee SE, Bae YS et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget 2015; 6: 2562–72.